April 9, 2018 / 8:54 PM / 2 months ago

BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease

April 9 (Reuters) - vTv Therapeutics Inc:

* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE

* VTV THERAPEUTICS INC - AZELIRAGON WAS GENERALLY WELL-TOLERATED IN STUDY

* VTV THERAPEUTICS INC - PHASE 3 STEADFAST STUDY DID NOT MEET EITHER CO-PRIMARY EFFICACY ENDPOINT

* VTV THERAPEUTICS - IS DISCONTINUING CURRENT CLINICAL STUDIES INVOLVING AZELIRAGON, INCLUDING OPEN-LABEL EXTENSION STUDY AND PART B OF STEADFAST STUDY​

* VTV THERAPEUTICS - WILL CONTINUE TO EVALUATE SUBSET DATA FROM PART A AND DATASET FROM PART B OF STEADFAST STUDY OVER COMING WEEKS

* VTV THERAPEUTICS - EXPECT SUBSTANTIAL PORTION OF PATIENTS IN PART B OF STEADFAST WILL HAVE COMPLETED 12 MONTHS OF TREATMENT UNDER STUDY PROTOCOL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below